ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
Eravacycline: evaluation of susceptibility testing methods and activity against multidrug-resistant Enterobacterales and Acinetobacter.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Resistance of Gram-Negative Bacteria to Eravacycline: A Systematic Review of Data from In Vitro Studies.Pathogens (Basel, Switzerland) · 2025Pooled it
- The Rise in Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026Review
- Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEravacycline is a tetracycline approved for treating intra-abdominal infections caused by multidrug-resistant (MDR) bacteria. Our study aims to compare two methods for determining eravacycline MIC against Gram-negatives and to evaluate its in vitro activity compared with various antibiotics, particularly last-line agents.
methodsWe performed susceptibility testing of eravacycline against 275 consecutive MDR Gram-negative clinical isolates collected by the Belgian NRC. The tested strains include Enterobacterales (n = 222) and Acinetobacter (n = 53) species, mostly carbapenemase producers. We used consecutively 111 of these strains to perform method comparison. ERV MICs were determined by broth microdilution (BMD) using Sensititre customized panel (ThermoFisher) and by gradient diffusion strip method (Etest Biomérieux).
resultsAccording to the BMD method, 83.3% of Enterobacterales were eravacycline susceptible (using EUCAST 2024 breakpoints for E. coli and FDA breakpoints) and 56.6% of Acinetobacter spp. below the ECOFF. For Enterobacterales, the CA, VMD, MD and EA were 98.4%, 1.64%, 0% and 100% respectively. For A. baumannii, we obtained 90% of CA, 88% of EA, 0% of VMD and 10% of MD. For Enterobacterales, eravacycline and tigecycline exhibited a MIC50 of 0.25 and 0.5 mg/L respectively. Colistin displayed a MIC50 of 0.5 mg/L while cefiderocol showed a MIC50 of 0.5 mg/L. 83.3%, 78.4%, 92.8% and 89.4% of Enterobacterales were eravacycline, tigecycline, colistin and cefiderocol susceptible respectively. For Acinetobacter spp., MIC50 was 0.25 mg/L for eravacycline; 0.5 mg/L for tigecycline; 1 mg/L for colistin and 0.25 mg/L for cefiderocol. 56.6%, 47.2%, 92.5% and 72.7% of Acinetobacter spp. were eravacycline, tigecycline, colistin and cefiderocol susceptible respectively.
conclusionGradient diffusion strip method provides accurate and reproductible eravacycline susceptibility results overall. Eravacycline may be an interesting therapeutical option against MDR Enterobacterales, with activity rate relatively similar to tigecycline and cefiderocol. Against MDR Acinetobacter spp., eravacycline displayed only moderate activity, despite one dilution lower MIC50 than tigecycline.
Indexed as
Identifiers
40824337What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.